Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Academic Article uri icon

Overview

publication date

  • July 14, 2020

Research

keywords

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides

Identity

PubMed Central ID

  • PMC7362378

Scopus Document Identifier

  • 85088699290

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2020001482

PubMed ID

  • 32589727

Additional Document Info

volume

  • 4

issue

  • 13